TickerHumSide-by-side comparison
AbbVie vs Merck & Co.
As of Nov 11, 2026, P/E is 50.8x for AbbVie vs 148.6x for Merck & Co.; P/S is 7.9x for AbbVie vs 5.4x for Merck & Co.; revenue growth is 10.7% for AbbVie vs 4.9% for Merck & Co.; net margin is 15.7% for AbbVie vs 3.6% for Merck & Co..
What stands out
- AbbVie is cheaper on earnings: 50.8x P/E vs 148.6x for Merck & Co..
- Merck & Co.'s shares did better over the past year: +60.9% vs +26.4% for AbbVie.
- AbbVie scores higher on TickerHum's ratings: 62/100 vs 50/100 for Merck & Co..
Key metrics
| Metric | ABBV | MRK |
|---|---|---|
| Price | $294.88 | $147.12 |
| Market cap | $521.23B | $362.69B |
| P/E | 50.8x (#1) | 148.6x (#2) |
| P/S | 7.9x (#2) | 5.4x (#1) |
| Revenue growth | 10.7% (#1) | 4.9% (#2) |
| Operating margin | 32.2% (#1) | — |
| Net margin | 15.7% (#1) | 3.6% (#2) |
| Debt / equity | — | 1.11 (#1) |
| 1-year return | +26.4% (#2) | +60.9% (#1) |
| Research score | 62/100 (#1) | 50/100 (#2) |
Higher is better for growth, margins, one-year return and overall score; lower is better for valuation and debt ratios. Ties share a rank and missing values are excluded.
Company research
- AbbVie Inc. (ABBV) — Drug Manufacturers—General
- Merck & Co., Inc. (MRK) — Drug Manufacturers—General